FIG 9.

Immune sera from animals vaccinated with HPIV3-EBOV or the trivalent vaccine block the binding of monoclonal antibodies specific for diverse GP epitopes. EBOV GP was bound to biosensors and then incubated with the indicated immune sera. The sensors were then incubated with antibodies known to bind GP. (A) The amounts of binding were measured by biolayer interferometry and are shown as percentages of the binding of a negative control (empty HPIV3 vector control sera). 2D22 is a human antibody specific for dengue virus. Mean values ± SEM are based on the results for 5 animals per group. Differences between blocking by mono- and trivalent sera were significant (P < 0.05) for all monoclonal antibodies except BDBV317. (B) Representative data curves for two samples. The negative-control value was determined by subtracting the value on the green line (no serum, no antibody) from the value on the blue line (no serum with antibody). The sample value was determined by subtracting the value for the red line (with serum, no antibody) from the value for the black line (with serum and antibody). The percent blocking was calculated by converting the sample value to a percentage of the negative-control value and subtracting from 100%.